Aliment Pharmacol Ther

1. ERIKSSON C, Sun J, Bryder M, Broms G, et al
   Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
   Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
   

   >> Share

   
   
2. VAN LIERE ELSA, de Boer NKH
   Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
   Aliment Pharmacol Ther. 2024;59:792-793.
   

   >> Share

   
   
3. VASUDEVAN A, Con D, van Langenberg DR
   Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
   Aliment Pharmacol Ther. 2024;59:794.
   

   >> Share

   
   

   
   Am J Gastroenterol

4. ANDERSON KL, Anand R, Feuerstein JD
   Insurance Companies' Poor Adherence to Guidelines for Moderate to Severe Ulcerative Colitis/Crohn's Disease Management.
   Am J Gastroenterol. 2024 Feb 29. doi: 10.14309/ajg.0000000000002720.
   

   >> Share

   
   

   
   BMC Gastroenterol

5. OH DJ, Hwang Y, Kim SH, Nam JH, et al
   Reading of small bowel capsule endoscopy after frame reduction using an artificial intelligence algorithm.
   BMC Gastroenterol. 2024;24:80.
   

   >> Share

   
   

   
   Clin Gastroenterol Hepatol

6. DUAN R, Zhang C, Li G, Li J, et al
   Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis.
   Clin Gastroenterol Hepatol. 2024 Feb 27:S1542-3565(24)00218.
   

   >> Share

   
   
7. GUPTA A, Peyrin-Biroulet L, Ananthakrishnan AN
   Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
   Clin Gastroenterol Hepatol. 2024;22:499-512.
   

   >> Share

   
   
8. BOYD T, Ananthakrishnan AN
   Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.
   Clin Gastroenterol Hepatol. 2024;22:659-661.
   

   >> Share

   
   

   
   Dig Dis Sci

9. KOLOSKI N, Shah A, Kaan I, Ben Jacob R, et al
   Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease.
   Dig Dis Sci. 2024 Feb 24. doi: 10.1007/s10620-024-08297.
   

   >> Share

   
   

   
   Eur J Gastroenterol Hepatol

10. KOSTEV K, Roderburg C, Loosen SH
    Inflammatory bowel disease is associated with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2024;36:498.
    

    >> Share

    
    
11. BAI Y, Sun Y, He Q, Bai X, et al
    Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024;36:359-370.
    

    >> Share

    
    
12. BHAYANA H, Sharma TK, Sharma A, Dhillon MS, et al
    Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1097/MEG.0000000000002735.
    

    >> Share

    
    
13. D'HAENS G, Baert F, Danese S, Kobayashi T, et al
    Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    Eur J Gastroenterol Hepatol. 2024;36:404-415.
    

    >> Share

    
    

    
    Gastroenterology

14. PEERY AF, Kelly CR, Kao D, Vaughn BP, et al
    AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.
    Gastroenterology. 2024;166:409-434.
    

    >> Share

    
    
15. DULAI PS, Singh S, Jairath V, Wong E, et al
    Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases.
    Gastroenterology. 2024;166:396-408.
    

    >> Share

    
    

    
    Gut

16. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    

    >> Share

    
    
17. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    

    >> Share

    
    

    
    Inflamm Bowel Dis

18. MARTINELLI M, Miele E, Staiano A
    Surgical Complications Need to Be Carefully Excluded Before Ruling Out a Diagnosis of De Novo Crohn's Disease.
    Inflamm Bowel Dis. 2024 Feb 24:izae026. doi: 10.1093.
    

    >> Share

    
    
19. QING X, Zhang C, Zhong Z, Zhang T, et al
    Causal Association Analysis of Periodontitis and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study.
    Inflamm Bowel Dis. 2024 Feb 26:izad188. doi: 10.1093.
    

    >> Share

    
    
20. DALAL RS, Winter RW, Gupta S, Sasson GF, et al
    Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States.
    Inflamm Bowel Dis. 2024 Feb 26:izae038. doi: 10.1093.
    

    >> Share

    
    
21. GONG T, Brew BK, Lundholm C, Smew AI, et al
    Comorbidity Between Inflammatory Bowel Disease and Asthma and Allergic Diseases: A Genetically Informed Study.
    Inflamm Bowel Dis. 2024 Feb 27:izae027. doi: 10.1093.
    

    >> Share

    
    
22. SWAMINATHAN A, Borichevsky GM, Frampton CM, Day AS, et al
    Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Feb 28:izae032. doi: 10.1093.
    

    >> Share

    
    
23. GREYWOODE R, Nahvi S, Ullman T, Keefer L, et al
    Feasibility and Acceptability of Digital Behavioral Interventions Among Black and Hispanic Patients With Inflammatory Bowel Disease: A Randomized Pilot Study.
    Inflamm Bowel Dis. 2024 Mar 1:izae034. doi: 10.1093.
    

    >> Share

    
    
24. OURANOS K, Saleem H, Vassilopoulos S, Vassilopoulos A, et al
    Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 Mar 1:izae031. doi: 10.1093.
    

    >> Share

    
    

    
    J Crohns Colitis

25. ROSH JR, Turner D, Hyams JS, Dubinsky M, et al
    Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease.
    J Crohns Colitis. 2024 Feb 26:jjae030. doi: 10.1093.
    

    >> Share

    
    
26. TORRES J, Colombel JF, Mary JY
    Lemman Index in Children: Still an Open Question.
    J Crohns Colitis. 2024;18:331-332.
    

    >> Share

    
    
27. GEBEYEHU GG, Taylor F, Dobson L, Cummings JRF, et al
    Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic survey.
    J Crohns Colitis. 2024;18:275-285.
    

    >> Share

    
    
28. GRANT RK, Jones GR, Plevris N, Lynch RW, et al
    Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset.
    J Crohns Colitis. 2024;18:286-290.
    

    >> Share

    
    
29. DHALIWAL J, Tertigas D, Carman N, Lawrence S, et al
    Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
    J Crohns Colitis. 2024;18:233-245.
    

    >> Share

    
    

    
    Lancet Gastroenterol Hepatol

30. NOOR NM, Lee JC, Bond S, Dowling F, et al
    A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
    

    >> Share

    
    
31. CHAPMAN TP, Ahmad T, Satsangi J
    Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
    Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
    

    >> Share

    
    

    
    PLoS One

32. JAMES JP, Riis LB, Sokilde R, Malham M, et al
    Short noncoding RNAs as predictive biomarkers for the development from inflammatory bowel disease unclassified to Crohn's disease or ulcerative colitis.
    PLoS One. 2024;19:e0297353.
    

    >> Share

    
    

    
    Scand J Gastroenterol

33. VIEUJEAN S, Gillard R, Delanaye P, Seidel L, et al
    Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's disease.
    Scand J Gastroenterol. 2024;59:296-303.
    

    >> Share

    
    
34. MIDJORD J, Nielsen KR, Vang AG, Strom M, et al
    Risk of malignancy in a high-incidence population-based cohort of Faroese patients with inflammatory bowel disease from 1960 to 2020 - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2024 Feb 26:1-8. doi: 10.1080/00365521.2024.2320712.
    

    >> Share

    
    

    
    Z Gastroenterol

35. KOLLECKER T, Nistal M, Waltz V, Ehard F, et al
    [Takayasu arteritis after COVID-19 infection in a 26-year-old female patient with Crohn's disease].
    Z Gastroenterol. 2024 Feb 28. doi: 10.1055/a-2187-9295.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share